ArticleClinical epigenetics2026
Identification of METTL3 and PRMT5 as an oncogenic pair for the prognosis and therapeutic targets of colorectal cancer subtype.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMETTL3 is a pivotal N6-methyladenosine (m⁶A) regulator that is linked to a worse prognosis of colorectal cancer (CRC). However, METTL3's oncogenic molecular networks in CRC remain unclear. This study aims to establish a co-expression network of METTL3 and identify novel diagnostic and therapeutic targets for CRC.
methodsWe integrated transcriptomic datasets with clinical cohorts and patient-derived organoids (PDOs) to evaluate the expression profiles of METTL3 and PRMT5. Mechanistic insights were gained through co-immunoprecipitation (Co-IP), m⁶A-methylated RNA immunoprecipitation (MeRIP), and Quantitative real-time PCR (qRT-PCR) assays. Single-cell and spatial transcriptomics were employed to resolve their spatial co-localization and cellular architecture. Furthermore, we performed patient stratification based on the METTL3/PRMT5 axis to characterize tumor microenvironment (TME) remodeling. The functional roles of these proteins in cell proliferation, mitochondrial fission, and mitophagy were validated in CRC cells and PDOs. Finally, the synergistic efficacy of the METTL3 inhibitor STM2457 and the PRMT5 inhibitor GSK591 was evaluated.
resultsWe identified a reciprocal positive feedback loop between METTL3 and PRMT5 that drives CRC malignancy: PRMT5 enhances METTL3 stability via symmetric dimethylarginine modification, while METTL3 facilitates PRMT5 expression in an m⁶A-dependent manner. Spatial and single-cell analysis revealed that their co-expression is spatially restricted and strongly correlates with an immunosuppressive TME. High METTL3/PRMT5 expression defines a specific molecular subtype characterized by accelerated cell cycle progression, DNA replication, and aberrant organelle fission. Critically, these phenotypes were functionally validated, showing that the METTL3/PRMT5 axis governs mitochondrial homeostasis. From a clinical perspective, CRC cell lines and PDOs with high METTL3/PRMT5 expression exhibited heightened sensitivity to combined inhibition with STM2457 and GSK591, revealing a potent therapeutic vulnerability.
conclusionOur findings establish METTL3 and PRMT5 as a pair of robust biomarkers for patient stratification and highlight the synergistic targeting of m⁶A and protein methylation as a promising precision oncology strategy for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.